EUCTR2016-003851-31-HU进行中（未招募）1 期
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, with Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia due to Nocturnal Polyuria in Adults - DAW
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Adults =18 years of age (at the time of written consent)
- •* Medical history of, or subject reported nocturia symptoms during the 6 months prior to Visit 1
- •* =2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior to Visit 2
- •* The largest single voided volume must be >250 mL (at least 1 void >250 mL) as documented in the 3-day e-Diary prior to Visit 2
- •* Nocturnal polyuria, defined as Nocturnal Polyuria index >33%, a ratio of Nocturnal Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in the 3-day e-Diary prior to Visit 2
- •* Bothered by nocturia as defined by an Nocturia Impact Diary Total Score of =10 points (raw score) as documented in the 3-day e-Diary prior to Visit 2
- •* =20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2) as documented in the 3-day e-Diary prior to Visit 3
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •* Current diagnosis of Obstructive Sleep Apnoea (OSA). In case of no current diagnosis of Obstructive Sleep Apnoea, high-risk subjects should be excluded as assessed by the STOP-Bang questionnaire at Visit 1
- •* Restless Legs Syndrome (RLS)
- •* History or suspicion of moderate to severe Lower Urinary Tract Symptoms with or without Bladder Outlet Obstruction. In case of suspicion of moderate or severe Lower Urinary Tract Symptoms with or without Bladder Outlet Obstruction, subjects should be excluded from the trial as follows:
- •? - All subjects with a Post-void Residual (PVR) >150 mL, as confirmed by ultrasound during screening prior to Visit 2
- •? - Male subjects who also have International Prostate Symptom Score (IPSS) =8 points and urinary flow <5 mL/s, as confirmed by uroflowmetry during screening prior to Visit 2
- •* Urinary incontinence defined as an average of >1 episode/day in the 3-day e-Diary prior to Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not necessarily exclusionary)
- •* Predominant daytime voiding dysfunction due to Overactive Bladder, at Visit 2, defined as:
- •? - Frequency (an average of >8 daytime voids per day during the 3-day diary period)
- •? - =1 daily urgency episode (the subject could not postpone voiding or the subject leaked before arriving to the toilet)
- •* Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy or female incontinence procedures
- •* Genito-urinary tract pathology that can in the investigator’s opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome, or stone in the bladder or urethra causing symptoms
- •* A history of cancer with the last date of disease activity/prescence of malignancy within the last 12 months prior to Visit 1, except for adequately treated basal cell carcinoma of the skin
- •* History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple Sclerosis, Parkinson’s, spinal cord injury, spina bifida)
- •* Habitual (fluid intake >3L per day) or psychogenic polydipsia
- •* Uncontrolled hypertension, as judged by the investigator
- •* Serum triglyceride level >400 mg/dL
- •* Uncontrolled diabetes mellitus, as judged by the investigator
- •* Central or nephrogenic diabetes insipidus
- •* Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion
- •* History of gastric retention
- •* Suspicion or evidence of congestive heart failure, (New York Heart Association [NYHA] class
- •II, III, IV)
- •* Hyponatraemia:
- •? - Serum sodium level <135 mmol/L at Visit 1(re-tested, with results available within 7 days)
- •? - Serum sodium level <130 mmol/L at Visit 3 (re-tested, with results available within 7 days)
- •* Use of any prohibited therapy listed below:
- •? - Current or former (within 3 months prior to screening) treatment with any other IMP
- •? - Unstable electrostimulation or behavioural bladder training program less than 3 months prior to screening (stable
- •electrostimulation or behavioural bladder training program started at least 3 months before screening are
- •acceptable)
- •? - Thiazide diuretics
- •? - Antiarrhythmic agents
- •? - V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasop
研究者
相似试验
进行中（未招募）
1 期
A trial to investigate efficacy, safety and tolerability of FE 201836 for Nocturia due to Nocturnal Polyuria in adultsocturia due to Nocturnal PolyuriaMedDRA version: 20.0 Level: LLT Classification code 10064016 Term: Nocturnal polyuria System Organ Class: 100000004857EUCTR2016-003851-31-BEFerring Pharmaceuticals A/S300
进行中（未招募）
1 期
A trial to investigate efficacy, safety and tolerability of FE 201836 for Nocturia due to Nocturnal Polyuria in adultsEUCTR2016-003851-31-CZFerring Pharmaceuticals A/S531
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisEUCTR2020-005764-62-ESHorizon Therapeutics Ireland DAC300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisEUCTR2020-005764-62-NLHorizon Therapeutics Ireland DAC300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisMedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859EUCTR2020-005764-62-GRHorizon Therapeutics Ireland DAC300